Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy - Summary - MDSpire

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

  • By

  • Miao Zhang

  • Haibin Yuan

  • Xindi Pan

  • Xian Li

  • Zichen Wang

  • Shuping Zhang

  • Zhigang Gu

  • Biao Hu

  • Xuedong Qu

  • Qian Wang

  • Xiangguo Gu

  • Bo Wang

  • Yu Cao

  • Guilin Mu

  • Guangbo Kang

  • Ario de Marco

  • Xiangshan Zhou

  • He Huang

  • June 10, 2026

  • 0 min

Share

Objective:

To develop novel anti-CD73 antibodies with dual mechanisms of action, including enzymatic blockade and receptor internalization, to disrupt the adenosine barrier in the tumor microenvironment.

Approach:
    Key Findings:
    • CR201 and CR202 bind to human and cynomolgus CD73, recognizing distinct structural domains, with CR202 targeting the N-terminal domain and CR201 targeting the C-terminal domain.
    • CR202 showed greater potency against membrane-bound CD73, while CR201 completely inhibited soluble CD73 activity.
    • Both antibodies restored T-cell proliferation and IFN-γ production and promoted CD73 internalization.
    • In vivo treatment with either antibody significantly suppressed tumor growth without observable toxicity.
    Interpretation:

    Limitations:
    • The study does not address potential long-term effects or the full range of immune responses.
    Conclusion:

    CR201 and CR202 represent next-generation therapeutic candidates for targeting the adenosine axis in cancer.

Original Source(s)

Dual-mechanism anti-CD73 antibodies CR201 and CR202 targeting distinct domains for cancer immunotherapy

  • by Miao Zhang, Haibin Yuan, Xindi Pan, Xian Li, Zichen Wang, Shuping Zhang, Zhigang Gu, Biao Hu, Xuedong Qu, Qian Wang, Xiangguo Gu, Bo Wang, Yu Cao, Guilin Mu, Guangbo Kang, Ario de Marco, Xiangshan Zhou, He Huang

  • June 10, 2026

Related Content

Editorial: Metabolic cell death in cancer: innovative therapeutic avenues for cancer treatment

Subcutaneous patient-controlled analgesia with hydromorphone for the treatment of refractory cancer pain in older hospitalized patients: a retrospective real-world study

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney